Cytokinetics, Incorporated
Price Action
Technical Summary
EMERGING TRENDCytokinetics, Incorporated is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is moderate (RS Rating: 73), indicating performance broadly in line with the market. Earnings contraction of 23% provides fundamental context to the price action. Investors should exercise caution due to high volatility (61% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $65.82 | +13.71% | ABOVE |
| 50 SMA | $63.98 | +16.98% | ABOVE |
| 100 SMA | $63.99 | +16.96% | ABOVE |
| 150 SMA | $63.36 | +18.12% | ABOVE |
| 200 SMA | $58.16 | +28.68% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CYTK in an uptrend right now?
CYTK has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is CYTK overbought or oversold?
CYTK's RSI (14) is 73. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is CYTK outperforming the market?
CYTK has a Relative Strength (RS) Rating of 73 out of 99. CYTK is performing about average compared to the market.
Where is CYTK in its 52-week range?
CYTK is trading at $74.84, which is 93% of its 52-week high ($80.20) and 89% above its 52-week low ($29.31).
How volatile is CYTK?
CYTK has a Beta of 0.66 and 52-week volatility of 61%. It's less volatile than the S&P 500 - generally more stable.